Skip to content
BY-NC-ND 3.0 license Open Access Published by De Gruyter Open Access August 9, 2011

Comparison of prostate cancer patient’s survival in Belarus and Lithuania

  • Giedre Smailyte EMAIL logo , Yury Averkin , Ilya Veyalkin , Sergey Krasny and Karolis Ulinskas
From the journal Open Medicine

Abstract

[1] Baade P.D., Youlden D.R., Krnjacki L.J., International epidemiology of prostate cancer: geographical distribution and secular trends, Mol. Nutr. Food. Res., 2009, 53, 171–184. http://dx.doi.org/10.1002/mnfr.20070051110.1002/mnfr.200700511Search in Google Scholar

[2] Ferlay J., Autier P., Boniol M., Heanue M., Colombet M., Boyle P., Estimates of the cancer incidence and mortality in Europe in 2006. Ann. Oncol., 2007, 18, 581–592. http://dx.doi.org/10.1093/annonc/mdl49810.1093/annonc/mdl498Search in Google Scholar

[3] Coebergh J.W.W., Sant M., Berrino F., Verdecchia A., Survival of adult cancer patients in Europe diagnosed from 1978–1989: the EUROCARE II study, Eur. J. Cancer, 1998, 34, 2137–2178. http://dx.doi.org/10.1016/S0959-8049(98)99063-310.1016/S0959-8049(98)99063-3Search in Google Scholar

[4] Berrino F., Capocaccia R., Coleman M.P., Estève J., Gatta G., Hakulinen T., et al., Survival of cancer patients in Europe. The EUROCARE-3 study, Annal. Oncol., 2003, 14(suppl 5), v9–155. http://dx.doi.org/10.1093/annonc/mdg75010.1093/annonc/mdg750Search in Google Scholar

[5] Coleman M.P., Gatta G., Verdecchia A., Estève J., Sant M., Storm H., et al., EUROCARE-3 summary: cancer survival at the end of 20th century, Annal. Oncol., 2003, 14(suppl 5), v128–149. http://dx.doi.org/10.1093/annonc/mdg75610.1093/annonc/mdg756Search in Google Scholar

[6] Ederer F., Axtell L.M., Cutler S.J., The relative survival rate: a statistical methodology, Natl. Cancer Inst. Monogr., 1961, 6, 101–121 Search in Google Scholar

[7] Dickman P., [Accessed 29 June 2009], Available at http://www.pauldickman.com. Search in Google Scholar

[8] Sant M, Capocaccia R, Coleman MP, Berrino F., Gatta G., Micheli A., et al., Cancer survival increases in Europe, but international differences remain wide, Eur. J. Cancer, 2001, 37, 1659–1667. http://dx.doi.org/10.1016/S0959-8049(01)00206-410.1016/S0959-8049(01)00206-4Search in Google Scholar

[9] Verdecchia A., Francisci S., Brenner H., Gatta G., Micheli A., Mangone L., et al., Recent cancer survival in Europe: a 2000–02 period analysis of EUROCARE-4 data, Lancet Oncol., 2007, 8, 784–796. http://dx.doi.org/10.1016/S1470-2045(07)70246-210.1016/S1470-2045(07)70246-2Search in Google Scholar

[10] Gondos A., Bray F., Brewster D.H., Coebergh J.W., Hakulinen T., Janssen-Heijnen M.L., et al., Recent trends in cancer survival across Europe between 2000 and 2004: a model-based period analysis from 12 cancer registries, Eur. J. Cancer, 2008, 44, 1463–1475. http://dx.doi.org/10.1016/j.ejca.2008.03.01010.1016/j.ejca.2008.03.010Search in Google Scholar PubMed

[11] Jemal A., Clegg L.X., Ward E., Ries L.A., Wu X., Jamison P.M., et al., Annual report to the nation on the status of cancer, 1975–2001, with a special feature regarding survival, Cancer, 2004, 101, 3–27. http://dx.doi.org/10.1002/cncr.2028810.1002/cncr.20288Search in Google Scholar PubMed

[12] Verdecchia A., Guzzinati S., Francisci S., De Angelis R., Bray F., Allemani C., et al., Survival trends in European cancer patients diagnosed from 1988 to 1999, Eur. J. Cancer, 2009, 45, 1042–1066. http://dx.doi.org/10.1016/j.ejca.2008.11.02910.1016/j.ejca.2008.11.029Search in Google Scholar PubMed

[13] Brenner H., Arndt V., Long-term survival rates of patients with prostate cancer in the prostate-specific antigen screening era: population-based estimates for the year 2000 by period analysis, J. Clin. Oncol., 2005, 23, 441–447. http://dx.doi.org/10.1200/JCO.2005.11.14810.1200/JCO.2005.11.148Search in Google Scholar PubMed

[14] Gondos A., Bray F., Hakulinen T., Brenner H., Trends in cancer survival in 11 European populations from 1990 to 2009: a model-based analysis, Ann. Oncol., 2009, 20, 564–573. http://dx.doi.org/10.1093/annonc/mdn63910.1093/annonc/mdn639Search in Google Scholar PubMed

[15] D’Ambrosio G., Samani F., Cancian M., De Mola C., Practice of opportunistic prostate-specific antigen screening in Italy: data from the Health Search database, Eur. J. Cancer Prev., 2004, 13, 383–386. http://dx.doi.org/10.1097/00008469-200410000-0000510.1097/00008469-200410000-00005Search in Google Scholar PubMed

[16] Etzioni R., Penson D.F., Legler J.M., Overdiagnosis due to prostate specific antigen screening: lessons from U.S. prostate cancer incidence trends, J. Natl. Cancer Inst., 2002, 94, 981–990. 10.1093/jnci/94.13.981Search in Google Scholar PubMed

[17] Gavin A., McCarron P., Middleton R.J., Savage G., Catney D., O’Reilly D., et al., Evidence of prostate cancer screening in a UK region, BJU Int., 2004, 93, 730–734. http://dx.doi.org/10.1111/j.1464-410X.2003.04716.x10.1111/j.1464-410X.2003.04716.xSearch in Google Scholar PubMed

[18] Kumar S., Shelley M., Harrison C., Coles B., Wilt T.J., Mason M.D., Neo-adjuvant and adjuvant hormone therapy for localised and locally advanced prostate cancer, Cochrane Database Syst. Rev., [2006CD006019]. 10.1002/14651858.CD006019.pub2Search in Google Scholar PubMed PubMed Central

[19] Mike S., Harrison C., Coles B., Staffurth J., Wilt T.J., Mason M.D., Chemotherapy for hormone-refractory prostate cancer, Cochrane Database Syst. Rev., [2006CD005247]. Search in Google Scholar

[20] Baade P.D., Youlden D.R., Krnjacki L.J., International epidemiology of prostate cancer: geographical distribution and secular trends, Mol. Nutr. Food Res., 2009, 53, 171–184. http://dx.doi.org/10.1002/mnfr.20070051110.1002/mnfr.200700511Search in Google Scholar PubMed

Published Online: 2011-8-9
Published in Print: 2011-10-1

© 2011 Versita Warsaw

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.

Downloaded on 1.3.2024 from https://www.degruyter.com/document/doi/10.2478/s11536-011-0058-5/html
Scroll to top button